ImmuCell Corporation Reports Q3 2026 Sales Increase to $8.0 Million
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2026. Total sales for the three months ended September 30, 2026, were $8.0 million, representing a 46.0% increase compared to the third quarter of 2025. Total sales for the nine months ended September 30, 2026, reached $25.6 million, a 27.8% increase over the nine months of 2025.
From manilatimes.net
Why it matters
The sales growth was attributed to the expansion of the sales team and improvements in commercial execution, according to Olivier te Boekhorst, President and CEO of ImmuCell Corporation. Growth was broad-based across the product portfolio, with Tri-Shield growing at 51% and Dual-Force growing at 36% during the third quarter.
From manilatimes.net
Who's involved
- ICCCAnimal health biologics company that reported Q3 2026 sales results
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
Related events
- Cboe Global Markets, Inc. filed a company disclosure with the SEC on October 25, 2026.
- Danaher Corporation filed a transaction disclosure with the SEC.
- MarketBeat monitored consensus ratings for Sasol, and insider transactions related to the company were disclosed to the SEC on May 27, 2026.
- SPYR plans to file a registration statement with the SEC after FM Financial Services audited its financial statements.
- The SEC requires listed firms to provide sustainability disclosures, impacting market disclosure rules.